Locations:
Search
Age alone should not rule out patients from potentially curative treatment
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic Cancer Institute takes multi-faceted approach to ensuring clinical trials representation
Dispelling myths and sharing practical experiences
Distinct molecular features found in five subtypes of disease
Patients who relapse early after first-line chemotherapy are often, but not always, refractory to second-line chemotherapy
A New Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Improving safety, efficacy and access for emerging therapies
Advertisement
Advertisement